HC Wainwright & Co. Reiterates Buy on Astria Therapeutics, Maintains $20 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Astria Therapeutics (NASDAQ:ATXS) with a Buy and maintains $20 price target.
MillerKnoll, Cleveland-Cliffs And Some Other Big Stocks Moving Higher On Thursday
U.S. stocks traded lower, with the Dow Jones dropping over 400 points on Thursday. Here are some big stocks recording gains in today’s session.
$10 Million Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed sharply higher on Wednesday, there were a few notable insider trades.
HC Wainwright & Co. Maintains Buy on Astria Therapeutics, Raises Price Target to $20
HC Wainwright & Co. analyst Joseph Pantginis maintains Astria Therapeutics (NASDAQ:ATXS) with a Buy and raises the price target from $13 to $20.
Dow Dips Over 800 Points; S&P 500 Down 2.8%
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 800 points.
Why Third Harmonic Bio Shares Are Trading Lower By Over 78%? Here Are 40 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Crown ElectroKinetics Corp. (NASDAQ: CRKN) jumped 69.6% to $0.2604 after gaining 17% on Wednesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.
RCI Hospitality, AbCellera Biologics And Some Other Big Stocks Moving Higher On Thursday
U.S. stocks traded lower, with the Dow Jones dropping over 600 points on Thursday. Here are some big stocks recording gains in today’s session.
Astria Therapeutics Announces Preliminary Results From The Phase 1a Clinical Trial Of STAR-0215 In Healthy Subjects
-- Shown Early Proof of Concept of STAR-0215's Profile as a Long-Acting Plasma Kallikrein Inhibitor with Estimated Half-Life of Up to 110 Days --
-- Plans to Initiate ALPHA-STAR Phase 1b/2 Trial in Hereditary
Astria Therapeutics Q3 EPS $(0.87) Down From $(0.61) YoY
Astria Therapeutics (NASDAQ:ATXS) reported quarterly losses of $(0.87) per share. This is a 42.62 percent decrease over losses of $(0.61) per share from the same period last year.
